In the regulated world of pharma and finance, shaping messages in the digital landscape can be a legal gauntlet, particularly when advisory bodies are slow to provide clear guidelines. In response, PR firms are helping businesses maneuver this murky area of communications.
"In the absence of guidelines, you have to create your own best practices," says Rohit Bhargava, SVP of the digital, strategy, and planning group at Ogilvy PR.
The Food and Drug Administration has delayed putting out ...